CE-IVDR: what it means for your diagnostics market entry strategy
CE-IVDR reshaped EU diagnostics market access in 2022. For US and Asian firms entering Europe, it is a commercial planning variable, not just compliance.
In May 2022, the European Union replaced its previous framework for in vitro diagnostic devices with a fundamentally more demanding regulation. Many manufacturers failed to complete the transition before their legacy certificates expired, resulting in products being withdrawn from the European market in the years that followed. For US and Asian diagnostics companies planning European market entry, CE-IVDR is not a compliance step to be addressed when the commercial plan is already set. It is a planning parameter that shapes the commercial plan from the start.
What changed and why it matters
The old framework, the In Vitro Diagnostic Directive (IVDD 98/79/EC), allowed manufacturers to self-certify most diagnostic products without third-party review. The new regulation, IVDR 2017/746, applies significantly stricter requirements across the board and requires independent review by an accredited third-party organisation, called a notified body, for the majority of diagnostics that international companies want to bring to market in Europe.
The practical consequences are specific and consequential. Clinical performance requirements are substantially higher than under the previous framework. Post-market surveillance obligations are more rigorous. Product registration is now mandatory in a centralised EU database called EUDAMED. And the pool of accredited notified bodies, the organisations authorised to conduct conformity assessments, contracted sharply after 2022 as many bodies failed to achieve IVDR designation. Where more than twenty notified bodies operated under the old directive, around a dozen were designated under IVDR as of 2024, a number that continues to evolve as more bodies complete the designation process.
One important element of the IVDR transition that many companies overlook is the set of transitional provisions that allow certain legacy devices to remain on the market under extended timelines. Under phased arrangements, some IVDs certified under the old directive can continue to be sold until 2027 or 2029, depending on device class and risk profile, provided specific conditions are met. Companies with existing IVDD-certified products should verify their specific transitional status with a regulatory specialist before assuming their current certification remains valid.
For a company accustomed to FDA clearance timelines, the European framework under IVDR is structurally different in ways that matter for planning. The FDA pathway has clearer timelines and more predictable review cycles. The IVDR pathway involves notified body queues, negotiated review processes, and a level of documentation depth that US companies frequently underestimate when they first assess European market entry.
CE-IVDR timelines are not a compliance detail. They are a commercial planning parameter. A company that has not factored them into its go-to-market timeline is not ready to execute that plan.
The four concepts a non-EU company needs to understand
Understanding CE-IVDR at a strategic level does not require mastery of the technical requirements. It requires clarity on four structural concepts.
Device classification
IVDR organises devices into four risk classes (A, B, C, D) based on intended use and impact on public health. Class determines the conformity assessment pathway, the evidence required, and notified body involvement. Most molecular diagnostics, NGS panels, and companion diagnostics fall in Class C or D. An incorrect classification discovered late creates significant rework.
Notified body
An accredited independent organisation that assesses whether a device meets IVDR. Choosing the right one is strategic, not logistical. Capacity, expertise, and queue length differ significantly. Initial review waits can exceed twelve to eighteen months. Pick the body before starting the technical file.
Clinical performance study
Structured evidence that the device performs as intended in its target population. Non-EU data can be accepted when adequately justified as representative of the European population, but the justification is subject to scrutiny. Site selection shapes both the regulatory submission and the commercial story.
EUDAMED
The centralised EU registry for devices, authorised representatives, and performance data. Roll-out is phased; not all modules are operational. For non-EU manufacturers, an EU Authorised Representative must be in place before registration can proceed.
Table — IVDR device classification: classes and life sciences examples
| Class | Risk level | NB review | Life sciences examples |
|---|---|---|---|
| A | Low | Not required (self-certified) | General laboratory reagents, specimen receptacles, non-sterile culture media |
| B | Moderate | Required | Blood glucose tests, pregnancy tests, urinalysis strips, basic haematology reagents |
| C | High | Required | Molecular diagnostics (PCR-based), NGS panels for oncology, HER2 testing, infectious disease diagnostics, blood group typing |
| D | Highest | Required + additional oversight | HIV, hepatitis B/C, HTLV blood screening tests; tests used for blood transfusion compatibility |
Most molecular diagnostics, NGS-based panels, companion diagnostics, and genomics tests used in oncology fall into Class C. Products at highest infectious disease risk (blood screening for transfusion) fall into Class D.
Table 1 — What changed: IVDD vs IVDR
| Dimension | IVDD, before 2022 | IVDR, from May 2022 |
|---|---|---|
| Self-certification | Allowed for most devices, including the majority of molecular diagnostics | Prohibited for Class C and D devices. Mandatory notified body review required. |
| Notified bodies designated | More than 20 active under IVDD | Around a dozen designated under IVDR (2024), number evolving |
| Clinical evidence required | Limited requirements for most device categories | Structured clinical performance studies mandatory for Class C and D |
| Post-market surveillance | Basic periodic reporting | Rigorous PMCF and PMPF obligations; continuous active monitoring required |
| Device registration | National registries, fragmented across member states | EUDAMED database; phased rollout, not all modules fully operational |
| Typical timeline to CE mark (complex diagnostics) | 6 to 18 months for most device categories | 18 to 36+ months for Class C and D devices |
| EU Authorised Representative | Required for non-EU manufacturers | Required for non-EU manufacturers before registration proceeds |
Table 2 — Regulatory comparison: EU (CE-IVDR) vs USA (FDA)
| Dimension | EU, CE-IVDR | USA, FDA |
|---|---|---|
| Regulatory framework | IVDR 2017/746, EU regulation, directly applicable in all member states | 21 CFR Part 820; pathways include 510(k), De Novo, and PMA |
| Review body | Private notified body, accredited by an EU member state. Manufacturer chooses the body. | FDA, a federal government agency. No choice of reviewer. |
| Third-party review required | Mandatory for Class C and D devices | Required for PMA (Class III). 510(k) and De Novo reviewed directly by FDA. |
| Typical review timeline | 18 to 36+ months for complex diagnostics, depending on notified body | 6 to 12 months for 510(k); 1 to 3 years for PMA |
| Clinical evidence | Clinical performance studies required for Class C and D | Varies by pathway; clinical studies required for PMA and many De Novo |
| Reimbursement link | Separate national processes in each EU country; no unified pathway | Separate Medicare/Medicaid coverage process; not linked to FDA clearance |
| Mutual recognition | No mutual recognition with FDA clearance. EU and US are separate processes. | No mutual recognition with CE-IVDR. FDA clearance does not satisfy EU requirements. |
| Self-certification path | Available for Class A devices only | Available for Class I 510(k)-exempt devices |
Why commercial strategy and regulatory strategy must run together
The most costly mistake US and Asian diagnostics companies make when planning European market entry is treating the regulatory pathway and the commercial strategy as sequential activities. Regulatory first, commercial second. In practice, this sequence is both slower and more expensive than running them in parallel, and it frequently produces regulatory submissions that satisfy the technical requirements but miss the commercial objectives.
Clinical performance studies, required under IVDR for most complex diagnostics, are the clearest example of where the two tracks must converge. A clinical study conducted at a hospital with the right patient volumes, the right clinical expertise in the relevant indication, and the right institutional relationships will generate data that serves both the regulatory submission and the commercial development simultaneously. The same study conducted at a site selected purely on logistical grounds generates regulatory data and nothing else.
In Italy specifically, the IRCCS network offers precisely this convergence. Italy's Istituti di Ricovero e Cura a Carattere Scientifico are hybrid research and clinical institutions that concentrate a disproportionate share of Italy's most complex cases, particularly in oncology and genomics. A clinical performance study conducted at a qualified IRCCS centre generates evidence that meets IVDR requirements, builds relationships with clinical opinion leaders who shape national adoption, and creates a commercial foothold in the Italian public healthcare market. The regulatory and commercial work happen in the same study, at the same institution, with the same investigators.
The companies that enter the European diagnostics market most efficiently are those that design their clinical performance studies to serve both the regulatory submission and the commercial strategy at the same time.
What this means for your planning timeline
CE-IVDR introduces timelines that non-EU companies consistently underestimate. The certification process for a complex diagnostic device involves notified body selection, technical file preparation, clinical performance study design and execution, submission review, and iterative clarification cycles. The total elapsed time from decision to CE marking varies significantly based on device class, the complexity of the performance evidence required, notified body capacity, and the quality of the initial submission.
The strategic implication is that CE-IVDR planning should begin eighteen to twenty-four months before the target date for first commercial activity in Europe, not after the commercial strategy is otherwise finalised. Companies that start the regulatory conversation late consistently find themselves with commercial commitments they cannot fulfil on the timelines they have communicated to distributors, hospital partners, and investors.
The technical navigation of CE-IVDR requires specialist regulatory expertise. What a commercial strategy advisor contributes to that process is not technical depth but coordination: ensuring the regulatory pathway is integrated into the commercial plan, that the clinical performance study sites are selected for both regulatory and commercial value, and that the overall timeline is realistic before commitments are made that depend on it. Leonardo Biondi works with international diagnostics companies on exactly this coordination, alongside a network of specialist regulatory advisors who cover the technical requirements in depth.
Like what you're reading?
Subscribe for more strategic notes on biotech and venture design.
Frequently asked questions
CE-IVDR is not the obstacle to European market entry. Treating it as separate from the commercial strategy is.
Book a 30-minute call